马来酸依那普利叶酸片对H型高血压的治疗效果评价

Clinical effect of enalapril maleate and folic acid tablets in treatment of H-type hypertension

目的评价马来酸依那普利叶酸片对H型高血压的治疗效果。方法本次研究中将我院心内科住院部2016年1月~2017年4月期间所收治300例H型高血压病患者作为研究对象。用数字随机表方法进行分组,对照组、观察组患者均为150例。纳入对照组中患者予以培哚普利片治疗,纳入观察组中患者予以马来酸依那普利叶酸片治疗。对比两组患者治疗前、后血压变化以及不良反应发生情况。结果治疗前两组患者收缩压、舒张压对比无显著差异(P>0.05);治疗后,观察组患者收缩压为(120.5±5.2)mm Hg,舒张压为(81.0±2.6)mm Hg,均显著低于对照组(P<0.05)。两组患者用药期间均未见明显不良反应,对照组1例患者出现轻微嗜睡症状,观察组1例患者出现轻微恶心呕吐症状,对比无显著差异(P>0.05),不具有统计学意义。结论用马来酸依那普利叶酸片对H型高血压患者进行治疗的效果理想,控制患者血压的效果确切,用药期间不良反应发生率低,用药安全可靠,有临床推广价值。

Objective To investigate the clinical effect of enalapril maleate and folic acid tablets in the treatment of H-type hypertension. Methods A total of 300 patients with H-type hypertension who were hospitalized in Department of Cardiology in our hospital from January 2016 to April 2017 were enrolled and divided into control group and observation group using a random number table, with 150 patients in each group. The patients in the control group were given perindopril tablets, while those in the observation group were given enalapril maleate and folic acid tablets. The two groups were compared in terms of the change in blood pressure after treatment and the incidence of complications. Results There were no significant differences between the two groups in systolic pressure and diastolic pressure before treatment （P〉0.05）, and after treatment, the observation group had significantly lower systolic pressure （120.5±5.2mmHg） and diastolic pressure （81.0±2.6mmHg） than the control group （P〈0.05）. No patient experienced marked adverse reactions. One patient in the control group experienced slight lethargy, and one in the observation group experienced slight nausea and vomiting; there was no significant difference between the two groups （P〉0.05）. Conclusion Enalapril maleate and folic acid tablets have an ideal effect in the treatment of H-type hypertension and can effectively control blood pressure. This drug is safe and reliable with a low incidence rate of adverse reactions. Therefore, it holds promise for clinical application.